IMAB vs. SYRS, AEON, MCRB, CRVO, RGLS, INCR, COYA, VTGN, PRQR, and SKYE
Should you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Syros Pharmaceuticals (SYRS), AEON Biopharma (AEON), Seres Therapeutics (MCRB), CervoMed (CRVO), Regulus Therapeutics (RGLS), InterCure (INCR), Coya Therapeutics (COYA), Vistagen Therapeutics (VTGN), ProQR Therapeutics (PRQR), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical preparations" industry.
I-Mab (NASDAQ:IMAB) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking and institutional ownership.
I-Mab currently has a consensus target price of $12.25, indicating a potential upside of 573.08%. Syros Pharmaceuticals has a consensus target price of $14.33, indicating a potential upside of 178.32%. Given I-Mab's higher probable upside, research analysts clearly believe I-Mab is more favorable than Syros Pharmaceuticals.
Syros Pharmaceuticals received 304 more outperform votes than I-Mab when rated by MarketBeat users. Likewise, 63.94% of users gave Syros Pharmaceuticals an outperform vote while only 62.92% of users gave I-Mab an outperform vote.
I-Mab has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.
In the previous week, Syros Pharmaceuticals had 3 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Syros Pharmaceuticals and 0 mentions for I-Mab. I-Mab's average media sentiment score of 0.00 beat Syros Pharmaceuticals' score of -0.50 indicating that I-Mab is being referred to more favorably in the media.
I-Mab has a net margin of 0.00% compared to Syros Pharmaceuticals' net margin of -1,656.34%. I-Mab's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.
38.4% of I-Mab shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Syros Pharmaceuticals has higher revenue and earnings than I-Mab.
Summary
I-Mab beats Syros Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get I-Mab News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
